Germany · Delayed Price · Currency is EUR Atossa Therapeutics Statistics
Total Valuation
FRA:YAG2 has a market cap or net worth of EUR 82.45 million. The enterprise value is 37.85 million.
| Market Cap | 82.45M |
| Enterprise Value | 37.85M |
Important Dates
The last earnings date was Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 129.17M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.39% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 19.40% |
| Float | 129.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.94 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.47 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.69 |
Financial Position
The company has a current ratio of 6.77
| Current Ratio | 6.77 |
| Quick Ratio | 6.30 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -48.89% and return on invested capital (ROIC) is -33.26%.
| Return on Equity (ROE) | -48.89% |
| Return on Assets (ROA) | -29.87% |
| Return on Invested Capital (ROIC) | -33.26% |
| Return on Capital Employed (ROCE) | -65.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.71M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.51% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -43.51% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 0.71 |
| Relative Strength Index (RSI) | 39.26 |
| Average Volume (20 Days) | 871 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.64 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.00M |
| Pretax Income | -25.72M |
| Net Income | -25.72M |
| EBITDA | -27.99M |
| EBIT | -28.00M |
| Earnings Per Share (EPS) | -0.20 |
Balance Sheet
The company has 44.19 million in cash and n/a in debt, giving a net cash position of 44.19 million.
| Cash & Cash Equivalents | 44.19M |
| Total Debt | n/a |
| Net Cash | 44.19M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 42.43M |
| Book Value Per Share | 0.33 |
| Working Capital | 40.44M |
Cash Flow
In the last 12 months, operating cash flow was -22.39 million and capital expenditures -13,637, giving a free cash flow of -22.41 million.
| Operating Cash Flow | -22.39M |
| Capital Expenditures | -13,637 |
| Free Cash Flow | -22.41M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:YAG2 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.39% |
| Shareholder Yield | -2.39% |
| Earnings Yield | -31.20% |
| FCF Yield | -27.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 20, 2018. It was a reverse split with a ratio of 0.0833333333.
| Last Split Date | Apr 20, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.0833333333 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |